A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

Table 2 Comparison of the clinical characteristics of patients with different dNLR-PNI grade

Variable	dNLR-PNI 0	dNLR-PNI 1	dNLR-PNI 2	P value
Variable	(n = 149)	(n = 296)	(n = 316)	P value
Age (y)	55.8 ± 12.9	54.0 ± 14.0	56.0 ± 13.1	0.15
Gender (male/ female)	131/ 18	252/ 44	259/ 57	0.304
BMI (Kg/m²)	22.9 ± 3.1	22.6 ± 3.3	22.3 ± 2.9	0.271
HBsAg (positive/ negative)	133/ 16	242/ 54	275/ 41	0.061
ALT (IU/L)	57.6 ± 49.9	60.9 ± 64.5	57.9 ± 50.8	0.758
AST (IU/L)	58.1 ± 43.1	72.5 ± 64.4	91.3 ± 76.3	< 0.001^b
TBIL (μmol/L)	18.0 ± 13.3	19.3 ± 11.7	24.7 ± 33.6	0.003^a
ALB (g/L)	43.1 ± 5.4	40.2 ± 6.1	35.3 ± 4.4	< 0.001^b
PT (s)	11.9 ± 1.41	12.4 ± 1.9	12.9 ± 1.6	< 0.001^b
INR	1.1 ± 0.1	1.1 ± 0.1	1.1 ± 0.1	0.175
Creatinine (μmol/L)	78.5 ± 15.6	79.9 ± 65.5	73.5 ± 20.4	0.168
Child-pugh grade (A/ B)	145/ 4	257/ 39	220/ 96	< 0.001^b
MELD score	5.6 ± 4.3	5.8 ± 5.0	6.3 ± 3.9	0.245
AFP (μg/L), ≤ 400/ > 400	92/ 57	176/ 120	182/ 134	0.69
Largest tumor size (cm)	6.3 ± 3.6	7.4 ± 3.8	9.2 ± 4.7	< 0.001^b
Tumor number (single/multiple)	61/ 88	119/ 177	133/ 183	0.93
Vascular invasion (absent/ present)	96/ 53	145/ 151	126/ 190	< 0.001^b
TACE treatments (1/ 2/ > 2)	60/ 38/ 51	128/ 76/ 92	165/ 81/ 70	0.026^a

dNLR derived neutrophil-to-lymphocyte ratio, PNI prognostic nutritional index, WBC white blood cells, BMI body mass index, ALT alanine transaminase, AST aspartate transaminase, ALB albumin, PT Prothrombin time, INR international normalized ratio, HBsAg hepatitis B surface antigen, AFP α-fetoprotein, TBIl total bilirubin, MELD the model for end stage liver disease
^aP < 0.05, when dNLR-PNI 2 vs. dNLR-PNI 0 and dNLR-PNI 1
^bP < 0.05 when each group compared with each other

ISSN: 1471-2407